A carregar...
Phase II Studies of Two Different Schedules of Dasatinib in Bone-Metastasis Predominant Metastatic Breast Cancer: SWOG S0622
PURPOSE: Bone metastases from breast cancer are common, causing significant morbidity. Preclinical data of dasatinib, an oral small molecule inhibitor of multiple oncogenic tyrosine kinases, suggested efficacy in tumor control and palliation of bone metastases in metastatic breast cancer (MBC). This...
Na minha lista:
| Publicado no: | Breast Cancer Res Treat |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5021222/ https://ncbi.nlm.nih.gov/pubmed/27475087 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-016-3911-z |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|